Trend outlook by mid-September will hit $74.50, following my own ideas and not paying attention to outside noise. Trials look promising, earning looking very good, and this stock is staying out of the norm for all that I have been reading. My view is that this investment, an opioid withdrawal treatment, will be beneficial for people and in the process help to fund...
